GlassScriptPhysician profile
Christopher Clarke
NPI 1013336940
$3,208.43
in general payments reported to CMS, 2019-2025
30 companies · $1,086 in 2025
The $1,086 reported for 2025 was more than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $206 · 2020: $246 · 2021: $355 · 2022: $227 · 2023: $517 · 2024: $572 · 2025: $1,086.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,174.58 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $764.84 | 2019-2025 | Ofev, Jascayd, Stiolto Respimat |
| Regeneron Healthcare Solutions, INC. | $432.61 | 2022-2025 | Dupixent |
| Glaxosmithkline, LLC. | $354.09 | 2019-2025 | Nucala, Trelegy Ellipta |
| Electromed, INC. | $311.42 | 2022-2025 | Smartvest |
| Astrazeneca Pharmaceuticals LP | $213.01 | 2020-2025 | Breztri, Airsupra |
| Genzyme Corporation | $197.15 | 2023-2025 | |
| Verona Pharma, INC. | $109.47 | 2025 | Ohtuvayre |
| Pfizer INC. | $74.38 | 2019-2023 | |
| Mylan Specialty L.P. | $67.54 | 2024 | Yupelri |
| Amgen INC. | $52.27 | 2020-2021 | |
| Gilead Sciences, INC. | $48.46 | 2019-2020 | |
| Lilly USA, LLC | $47.07 | 2021-2025 | Mounjaro, Zepbound |
| Mannkind Corporation | $44.84 | 2019 | |
| Viatris Specialty LLC | $44.11 | 2025 | Yupelri |
| Axsome Therapeutics, INC. | $43.55 | 2025 | Sunosi |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $38.50 | 2020-2025 | Glassia |
| Novo Nordisk INC | $38.09 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $35.06 | 2019-2020 | |
| Insmed, INC. | $34.46 | 2023 | Arikayce |
| Jazz Pharmaceuticals INC. | $31.93 | 2023 | |
| Beta Bionics, INC. | $31.32 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Abbvie INC. | $28.09 | 2021 | |
| Ani Pharmaceuticals, INC. | $26.77 | 2023 | Purified Cortrophin Gel |
| Inspire Medical Systems, INC. | $26.41 | 2025 | Inspire |
| Mallinckrodt Hospital Products INC. | $24.76 | 2020 | |
| Neurocrine Biosciences, INC. | $24.42 | 2025 | |
| Genentech USA, INC. | $17.07 | 2021 | |
| Philips North America LLC | $16.94 | 2025 | Vest Therapy Und |
| Actelion Pharmaceuticals US, INC. | $15.50 | 2021 | |
| Inogen, INC. | $14.30 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Clarke listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.